tbuckley/cabot-search huggingface dataset:
AB0113 SEX DIFFERENCES IN CLINICAL FEATURES AND MORTALITY RATE IN GOUT: A NATIONWIDE RETROSPECTIVE COHORT STUDY
Authors: H. Do, K. Choe, M. J. Kim, K. Shin, K. W. Moon
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Gout is an inflammatory arthritis that occurs when uric acid crystals crystallize in the joints, frequently linked to elevated levels of uric acid in the body. It is well-known to have a significantly higher incidence rate in men compared to women. Gout patients may have several other coexisting conditions, and these conditions can have an impact on the gout status and mortality. <h3>Objectives:</h3> Studies on gout in women have been conducted so far; however, there has been a lack of large-scale research in women with gout related to mortality. In this study, we analyzed the sex-based differences in mortality rates among patients with gout in Korea and identified the causes of death. Furthermore, we aimed to analyze the factors contributing to the sex-based differences in the causes of death. <h3>Methods:</h3> This study based on patients collected from the National Sample Cohort (NHIS-NSC) database. The study included aged 20 or older who were diagnosed as gout and received urate lowering agents (allopurinol, febuxostat, or benzbromarone) at least once. Analysis was performed to find risk factor for mortality and calculate hazard ratio (HR) for overall mortality. <h3>Results:</h3> The study included 15838 male and 3116 female. No significant difference in mortality was observed between males and females. There was a significant difference observed in age at drug start (Hazard ratio = 1.09, 1.10, respectively). The presence of underlying conditions showed a significant increase in mortality (P &lt;0.0001, all). Hazard ratio was 1.88 for malignancy, 1.37 for diabetes mellitus, 1.97 for chronic kidney disease, 1.28 for cerebrovascular disease indicating significant increase in mortality (P &lt;0.0001, all). <h3>Conclusion:</h3> The mortality rate was higher in female patients with gout. Difference in mortality rates between male and female patients with gout might be due to differences in age and underlying disease condition rather than sex difference itself. <h3>REFERENCES:</h3> <b>NIL.</b> <h3>Acknowledgements:</h3> <b>NIL.</b> <h3>Disclosure of Interests:</h3> <b>None declared.</b>
AB0648 METABOLOMICS IN RHEUMATOID ARTHRITIS WITH VERSUS WITHOUT DISEASE-MODIFYING ANTIRHEUMATIC DRUG INITIATION
Authors: S. Patschan, I. Claus, M. Hoffmeister, S. Strathmeyer, S. Heelemann, C. Remus, W. Dammermann, O. Ritter, D. Patschan
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Rheumatoid arthritis (RA) significantly increases the overall risk of cardiovascular disease (CVD). In addition to conventional risk factors, the inflammatory activity of the disease itself and medications that promote atherosclerosis contribute to an even greater risk. However, there is a lack of additional biomarkers for CVD risk assessment. In recent years, metabolomics has emerged as a valuable tool for identifying potential biomarkers in various diseases. <h3>Objectives:</h3> In this study, we conducted metabolomics analysis in RA patients, both with and without disease-modifying antirheumatic drug initiation (DMARD) therapy. <h3>Methods:</h3> Observational, cross-sectional investigation that included patients with established RA. DMARD therapy, if prescribed, consisted of methotrexate alone or in combination with other cDMARDs or bDMARDs or other cDMARDs or bDMARDs without MTX, respectively. Metabolomic profiling was conducted using a Bruker AVANCE NEO 600 MHz NMR spectrometer. The spectra obtained were Fourier transformed using TopSpin software (version 4.0, Bruker Biospin, Germany). All spectra were automatically phased and subjected to baseline correc-tion. Subsequently, the spectra were analyzed using the proprietary Profiler software (version 1.4_Blood, lifespin GmbH, Germany) and a quantitative metabolite list was generated. <h3>Results:</h3> In total, 47 patients with untreated and 153 individuals with DMARD-treated RA were included. In general, RA patients with arterial hypertension showed higher glucose and mannose levels than non-hypertensive subjects. Also, diabetics displayed significant differences between several intermediates (n=15) of the amino acid and lipid metabolism. Patients with a Framingham score of 20+ showed 19 distinct metabolic aberrations from individuals with a score of below 10. Finally, the following metabolites significantly differed between DMARD- and DMARD+ RA: 1,2-propanediol, glycerol, high density lipoprotein, and leucine. <h3>Conclusion:</h3> Our findings have aided in the identification of potential surrogate markers for assessing the burden of cardiovascular disease in individuals with RA. Selected candidates may have the potential to enhance the accuracy of cardiovascular risk assessment in RA thus allowing for a more comprehensive evaluation. <h3>REFERENCES:</h3> <b>NIL.</b> <h3>Acknowledgements:</h3> <b>NIL.</b> <h3>Disclosure of Interests:</h3> Susann Patschan: None declared, Inga Claus: None declared, Meike Hoffmeister: None declared, Selina Strathmeyer Lifespin GmbH, Steffen Heelemann Lifespin GmbH, Constantin Remus: None declared, Werner Dammermann: None declared, Oliver Ritter: None declared, Daniel Patschan: None declared.
AB0709 RHEUMATOID ARTHRITIS AND SELF ESTEEM: A CROSS SECTIONAL STUDY ABOUT TUNISIAN PATIENTS
Authors: M. Brahem, A. Ben Salem, O. Jomaa, R. Sarraj, M. Ardhaoui, B. Jebali, O. Farhat, M. Younes
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Rheumatoid arthritis (RA) is a common chronic inflammatory disease, that causes physical restrictions and functional disability. These disorders can lead to low self-esteem. <h3>Objectives:</h3> Our study aimed to determine the frequency of low self-esteem in patients with RA and its associated factors. <h3>Methods:</h3> A cross sectional study including RA patients, which consulted or were hospitalized in the Rheumatology department at Taher Sfar Hospital in Tunisia, was conducted. The diagnosis of RA was based on ACR/EULAR 2010 criteria. Socio-demographic and clinical data including disease activity (DAS 28), Visual Analog Scale for pain (VAS pain), Health Assessment Questionnaire (HAQ) were collected. The level of self-esteem was assessed using the Rosenberg Self-esteem Scale (RSES). Patients have reported their agreement, on a five-point Likert scale (0 = strongly disagree, 4 = strongly agree) on 10 statements concerning self-perceived aspects of self-esteem. Total scores range from 10-40. A general score less than 31 defined a low self-esteem rate. <h3>Results:</h3> We included in our study 65 patients: 60 Females and 5 males with a mean age of 54.2 ±12 [24-80 years]. The average duration of the disease was 12.6 ± 7.7 [6 months-37 years]. The average VAS pain and HAQ were 19.5 ± 21 [0-90 mm] and 0.7± 0.5 [0-2] respectively. The mean DAS 28 was 3.1 ± 1.2 [1.1-6.3]. RA was erosive (83.1%), seropositive (79.9%), and with specific deformities (49.2%). In 34.9 % of cases, there was low self-esteem according to the RSES Questionnaire with a mean RSES of 30.4 ± 5.8 [15-40]. Low self-esteem was significantly associated with a high activity of the RA (p=0.006), an important functional disability (p=0.02) and greater pain severity VAS pain (p=0.006). No significant associations were found between RSES on the one hand and the age (p=0.5) or the disease duration (p=0.2) on the other hand. <h3>Conclusion:</h3> Our study showed that low self-esteem is frequent in patients with RA and this trouble was related essentially to active disease and functional disability. Screening for this disorder and the management of the RA activity will be necessary during follow-up of our patients to ameliorate their quality of life and to bolster self-esteem in the ongoing context of self-care. <h3>REFERENCES:</h3> <b>NIL.</b> <h3>Acknowledgements:</h3> <b>NIL.</b> <h3>Disclosure of Interests:</h3> <b>None declared.</b>
AB0675 NON-INVASIVE ASSESSMENT OF MICRO- AND MACROVASCULAR FUNCTION AFTER INITIATION OF JAK INHIBITORS IN PATIENTS WITH RHEUMATOID ARTHRITIS
Authors: P. Anyfanti, E. Angeloudi, E. Pagkopoulou, E. Bekiari, M. Doumas, P. Avgerou, K. Defteraiou, G. Kitas, T. Dimitroulas
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Janus kinase (JAK) inhibitors represent a novel class of oral biologic disease-modifying anti-rheumatic drugs for the treatment of rheumatoid arthritis (RA). However, their cardiovascular safety profile is concerning regarding major adverse cardiovascular and venous thromboembolic events. Potential mechanisms implicate vascular alterations, yet the effects of JAK inhibitors on the micro- and macrocirculation remain largely understudied. <h3>Objectives:</h3> In this prospective observational study, we investigated whether treatment with JAK inhibitors in RA is associated with significant alterations in the micro- and microvasculature within 3 months' time. <h3>Methods:</h3> Thirteen RA patients initiating JAK inhibitors as per treating physician decision were stuided. Eventually, 11 patients who completed the study were included in data analysis. Clinical parameters, disease activity and biochemical markers were assessed. Participants underwent 24h ambulatory blood pressure monitoring (Mobil-O-Graph device) for the assessment of 24h, day- and nighttime blood pressure (both brachial and aortic) and markers of large artery stiffening [pulse wave velocity (PWV), augmentation index]. Carotid intima media-thickness was measured with ultrasound. Nailfold videocapillaroscopy was applied to assess a number of capillaroscopic parameters. All procedures were performed at baseline and repeated 3 months after treatment. <h3>Results:</h3> Treatment with JAK inhibitors was not associated with any differences in brachial and aortic blood pressure, as assessed throughout the whole 24h, daytime and nighttime period. Markers of macrovascular function and morphology (arterial stiffness, carotid atherosclerosis) remained unaltered, with the only exception of nighttime PWV which was significantly elevated at follow-up (Table 1). However, treatment with JAK inhibitors significantly decreased venous capillary limb, apical width and capillary length, and increased the number of ramified capillaries and the total number of abnormalities (Table 2). <h3>Conclusion:</h3> Treatment with JAK inhibitors may exert significant effects on microcirculation as assessed with nailfold videocapillaroscopy within three months' time, whereas macrovascular structure and function appear largely unaffected. Whether alterations in the microvasculature induced by JAK inhibitors may mediate increased cardiovascular risk warrants further investigation. <h3>REFERENCES:</h3> <b>NIL.</b> <h3>Acknowledgements:</h3> <b>NIL.</b> <h3>Disclosure of Interests:</h3> <b>None declared.</b>
AB1097 LUPUS MYOCARDITIS: INITIAL PRESENTATION AND OUTCOMES IN A MONOCENTRIC SERIES OF 12 PATIENTS
Authors: H. Hanani, W. Ammouri, L. Kherroubi, S. Belkhettab, N. Mouatassim, H. Khibri, M. Maamar, H. Harmouche, Z. Tazi Mezalek, M. Adnaoui
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Cardiac manifestations of systemic lupus erythematosus (SLE) can affect all three layers of the heart, vavular tissues and coronary arteries; acute myocarditis is rare but potentially fatal. <h3>Objectives:</h3> Our aims were to describe the clinical, biological and radiological features of lupus myocarditis as well as therapeutic and longterm outcomes. <h3>Methods:</h3> Monocentric retrospective observational study carried out in Ibn Sina University Hospital Center from January 2010 to June 2023 including patients over 16 years old meeting the ACR criteria for systemic lupus erythematosus (SLE) and presenting with acute myocarditis. <h3>Results:</h3> Twelve of 511 SLE patients (2.3 %) met the study criteria, with eleven women (91.6%) and a median age at SLE diagnosis of 29.5 years (IQR: 28.8 - 37). Among them, 12.5% were hypertensive, 12.5% diabetic and 20% had a familial autoimmune condition. Myocarditis was the first sign of SLE in 40% of patients. The main symptoms were chest pain (75%) and dyspnea (57.1%). Pericardium effusion was associated in 50% of patients. The main extracardiac manifestations were: arthralgia (87.5%), skin lesions (75%), neuropsychiatric involvement (62.5%), renal involvement (25%) and pleural effusion (25%), with general signs in 50% of patients. The mean initial SLEDAI was 14 (severe SLE disease activity index). Echocardiography revealed low left ventricular ejection fraction (&lt; 50%) in 91.7% and wall motion abnormalities in 50% of patients; electrocardiogram showed a microvoltage in two patients (16.7%). Laboratory results revealed elevated troponin in all patients, antinuclear antibody titer higher than 1/320 in all patients, with a median lymphocyte count of 1000 elements/mm3 and median C-reactive protein level of 24 mg/L. All patients were put on prednisone; 57.1% received immunosuppressive treatment including cyclophosphamide (42.9%), mycophenolate mofetil (28.6%) and azathioprine (28.6%). Half of patients received heart failure treatment. Nine patients (75 %) are still regularly monitored in the same center and five are in remission. One patient progressed to endomyocardial fibrosis on MRI. Three patients were lost to follow-up. No deaths have been reported to date. <h3>Conclusion:</h3> Lupus myocarditis can often be the first manifestation of the disease or can occur during follow up. The severity of myocardial damages requires an early diagnosis for an adequate management, immunosuppression being the therapeutic cornerstone. <h3>REFERENCES:</h3> <b>NIL.</b> <h3>Acknowledgements:</h3> <b>NIL.</b> <h3>Disclosure of Interests:</h3> <b>None declared.</b>
AB0696 IMPACT OF INCIDENT RA ON TRAJECTORIES FOR EARNINGS: NATIONWIDE SIBLING COMPARISON STUDY
Authors: H. Miller, M. Neovius, J. Askling, G. Bruze
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> RA significantly impacts individuals' lives, yet its specific effects on economic trajectories, particularly earnings, remain underexplored. <h3>Objectives:</h3> To examine the long-term effects of incident RA on individuals' earnings. <h3>Methods:</h3> Swedish register data were used, including demographic information, taxed earnings (€), healthcare use, and medication prescriptions. Participants were RA patients aged 30-60y diagnosed between 2006 and 2017. Patients with a diagnosis of RA were compared to same-sex siblings (n=2467:2467; mean 48y; 72% women). Earnings data from 2001-2019 were retrieved from Statistics Sweden. <h3>Results:</h3> Patients with RA and their siblings had similar earnings prior to the year of diagnosis (Figure 1). During the year of diagnosis and thereafter, statistically significantly lower earnings were observed in patients with RA compared to their siblings (5.8% or €1369 [95%CI 660-2078] less per year than same-sex siblings; Figure 1). Patients diagnosed before 2011 earned significantly less than siblings (8.8% or €1879 [95%CI 967-2791] less per year than same-sex siblings). However, for patients diagnosed after 2011, there was no significant difference in earnings compared to their siblings (2.4% or €562, [95%CI -394-1519] less per year than same-sex siblings). Subgroup analyses showed that the negative impact on earnings was stronger for older individuals, women, and those with lower education levels. <h3>Conclusion:</h3> RA diagnosis was associated with lower earnings, particularly for older individuals, women, and those with lower education levels. Notably, patients diagnosed before 2011 had lower earnings, while those diagnosed after 2011 did not, compared to sibling comparators. <h3>REFERENCES:</h3> <b>NIL.</b> <h3>Acknowledgements:</h3> <b>NIL.</b> <h3>Disclosure of Interests:</h3> Heather Miller: None declared, Martin Neovius Participation in talks as advisory board member between 2011-2016, Independent consultant before 2009, Agreements between Karolinska Institutet (with JA as PI) and Abbvie, BMS, Eli Lilly, Galapagos, MSD, Pfizer, Roche, Samsung Bioepis, Sanofi, mainly for the national safety monitoring of rheumatology immunomodulators in Sweden (ARTIS), Johan Askling Agreements between Karolinska Institutet (with JA as PI) and Abbvie, BMS, Eli Lilly, Galapagos, MSD, Pfizer, Roche, Samsung Bioepis, Sanofi, mainly for the national safety monitoring of rheumatology immunomodulators in Sweden (ARTIS), Gustaf Bruze Agreements between Karolinska Institutet (with JA as PI) and Abbvie, BMS, Eli Lilly, Galapagos, MSD, Pfizer, Roche, Samsung Bioepis, Sanofi, mainly for the national safety monitoring of rheumatology immunomodulators in Sweden (ARTIS).
AB0662 THE ULTRASOUND 7 SCORE IN THE ASSESSMENT OF SYNOVITIS IN RHEUMATOID ARTHRITIS CORRELATION WITH CLINICAL DISEASE ACTIVITY INDICES IN DAILY IN LATIN AMERICA DAILY RHEUMATOLOGIC PRACTICE
Authors: V. M. Torres Toapanta, O. Sedano, R. Estigarribia, E. Martinez, J. Tordoya
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Grey-scale and power Doppler ultrasonography are extensively used to detect synovial inflammation and appreciate disease activity, in addition to clinical and laboratory data, in order to apply the proper therapeutic measures, monitor the patients and assess the outcome [1]. <h3>Objectives:</h3> The aim of the paper was to assess value of ultrasound 7 score (US7) in the detection of synovitis in rheumatoid arthritis (RA) and its correlation with clinical disease activity indices CDAI. <h3>Methods:</h3> A total of 120 patients with suspicion or diagnosis of RA were included. Disease activity was assessed by clinical disease activity indices CDAI. Erythrocyte sedimentation rate was measured, and simple erosion narrowing score was used for radiography scoring. Musculoskeletal US7 score was done which combines each joint score for synovial proliferation (gray-scale ultrasound GSUS7) and vascularization (power Doppler ultrasound PDUS7). <h3>Results:</h3> Detailed joint region examination by US7 score was done. Dorsomedian aspect of wrist (92%), dorsal aspect of metacarpophalangeal joint (MCP) II (96%), and dorsal aspect of phalangeal interproximal (PIP) II and III (92%), dorsal aspect of metatarsophalangeal (MTF)II (99%) and V (89%) were the most affected joint regions with synovitis by GSUS. However, for detection of synovitis by PDUS, dorsomedian aspect of wrist and dorsal aspect of MCP, PIP II, and PIP III were involved (45%). Erosions were found most in radial aspect of MCP II (70%), lateral aspect of metatarsophalangeal joint V (72%), and dorsal aspect of PIP II (64%) and PIP III (43%). All clinical disease activity indices CDAI were correlated with GSUS7 and PDUS7 synovitis. Our results show a positive, moderate inter-relation, for both GSUS (p=0.67, statistically significant, p=0.009), and PDUS score (r= 0.5279, p= 0.0006), <h3>Conclusion:</h3> US7 was simple and practical sum scoring system for use in the detection of synovitis in patients with RA. The correlations between the clinical disease activity indices, erythrocyte sedimentation rate, duration of illness, radiographic score, and components of the US7 score reflects the value of US7 score in assessment of disease activity and severity. <h3>REFERENCES:</h3> [1] Backhaus M, Ohrndorf S, Kellner H, et al. Evaluation of a novel 7-joint ultrasound score in daily rheumatologic practice: a pilot project. Arthritis Rheum. 2009;61(9):1194–1201. <h3>Acknowledgements:</h3> SOCIEDAD PERUANA DE REUMATOLOGIA. <h3>Disclosure of Interests:</h3> <b>None declared.</b>
Geographic Mapping of Gender Disparities in Authorship of Cardiovascular Literature
Authors: Ridhima Goel, Samantha Sartori, Birgit Vogel, Kimberly Okoli, Kayla Franklin-Bedel, Rebecca Ortega, Dee Dee Wang, Pamela S. Douglas, Tracy Y. Wang, Roxana Mehran
Journal: Journal of the American College of Cardiology (2024)
POS0459 PANTREG: A CELL-THERAPY, SYSTEM-BIOLOGY - BASED APPROACH FOR THERAPY OF AUTOIMMUNITY
Authors: S. Albani, Y. Zhao, D. Guo, M. Chew
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> DMARDS and biologics are the cornerstone of therapy of autoimmunity and GVHD. However, a sizeable proportion of patients remains still with unsatisfactory disease control. Gliding on the relative success in Cancer, cell therapy is now being developed for autoimmunity. Current efforts for CarTreg are mostly focused on engineering patient's Treg specific for a single antigen, deemed relevant for the etiopathogenesis of the disease, These approaches have inherent imitations. <h3>Objectives:</h3> To engineer and test <i>in vitro</i> and in humanised mouse models of GVHD and autoimmune disease CarTreg which: i) home to microenvironments where inflammatory cytokines are present, and ii) are induced by such inflammatory cytokines in producing locally tolerogenic cytokines, thus inducing immune tolerance, with an effective clinical control based on the induction of active immune tolerance. <h3>Methods:</h3> We have engineered a first in class lentivirus (PanTreg herein) which: a) binds specifically pro-inflammatory cytokines such as TNF and IFN; b) upon binding, induces expression of FoxP3, TGFb and IL-10 in transfected human polyclonal T cells (Gen1 PanTreg). We have developed and validated this construct <i>in vitro</i> and <i>in vivo</i> in a humanised model of GVHD. <h3>Results:</h3> <b>PanTreg are effective in reducing human T effector function in vitro:</b> We compared polyclonal untransduced Treg and PanTreg from the same individuals (n=5) for their ability to reduce Teff activation and Teff proliferation (Figure 1) <b>PanTreg are highly effective in controlling signs and outcomes of a humanised model of GVHD:</b> We chose to test our TNF-specific scFv first in a humanised model of GFVD where TNF is relevant for the pathogenies. As shown in figure 2, below, we tested two different does of PanTreg and compared their efficacy against autologous polyclonal, untransduced Treg, with encouraging results in a dose-dependent fashion. We also show in figure 2D the effects of PanTreg on the proliferation <i>in vivo</i> of human effector T cells. <h3>Conclusion:</h3> We describe here our initial experience with a first in class type of CarTreg, where the scFv is specific for an inflammatory cytokine. This approach has the potential to provide with a single construct an innovative approach, and perhaps a permanent solution, to many diseases, in which such cytokines are relevant, by inducing active tolerance rather than suppressing, or "sponging out" the relevant cytokine. <h3>REFERENCES:</h3> <b>NIL.</b> <h3>Acknowledgements:</h3> <b>NIL.</b> <h3>Disclosure of Interests:</h3> <b>None declared.</b>